The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
 
Pamela L. Kunz
Stock and Other Ownership Interests - Guardant Health
Consulting or Advisory Role - Ipsen; Lexicon
Research Funding - Advanced Accelerator Applications (Inst); Dicerna (Inst); Esanex (Inst); Genentech/Roche (Inst); Incyte (Inst); Ipsen (Inst); Lexicon (Inst); Merck (Inst); Oxigene (Inst)
 
Paul J. Catalano
Consulting or Advisory Role - Lilly
 
Halla Nimeiri
Speakers' Bureau - Genentech/Roche
 
George A. Fisher
Stock and Other Ownership Interests - Seattle Genetics (I)
Honoraria - Genentech; Ipsen; Merck; Novartis
Consulting or Advisory Role - Genentech/Roche; ipsen; Merck
Research Funding - Aduro Biotech (Inst); EpicentRx (Inst); Forty seven (Inst); Genentech/Roche (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Teri A. Longacre
No Relationships to Disclose
 
Carlos J. Suarez
No Relationships to Disclose
 
James C. Yao
No Relationships to Disclose
 
Matthew H. Kulke
Consulting or Advisory Role - Ipsen; Lexicon; Novartis
Research Funding - Ipsen
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Ipsen; Novartis; Perthera; Xbiotech
Travel, Accommodations, Expenses - Halozyme
 
James Christopher Shanks
No Relationships to Disclose
 
Manisha H. Shah
Consulting or Advisory Role - Eisai; Loxo; Novartis
Research Funding - Eisai; Loxo; Merck
 
Mark Zalupski
Research Funding - Halozyme; Newlink Genetics/Pharmatech; Oncomed
 
Edmond L. Schmulbach
No Relationships to Disclose
 
Diane Lauren Reidy
Honoraria - Novartis
Consulting or Advisory Role - Ipsen; Novartis; Pfizer
Research Funding - Novartis
 
Jonathan R. Strosberg
Honoraria - Novartis
Consulting or Advisory Role - Ipsen; Lexicon; Novartis
Speakers' Bureau - Ipsen; Lexicon
Research Funding - Novartis; Pharmacyclics
Travel, Accommodations, Expenses - Advanced Accelerator Applications
 
Peter J. O'Dwyer
Consulting or Advisory Role - Bristol-Myers Squibb; Five Prime Therapeutics; Forty Seven; Genentech
Research Funding - Amgen; Bayer; BBI Healthcare; Bristol-Myers Squibb; Celgene; Five Prime Therapeutics; Forty Seven; Genentech; GlaxoSmithKline; Merck; Mirati Therapeutics; Novartis; Pfizer; Pharmacyclics
 
Al Bowen Benson
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Celgene; EMD Serono; Exelixis; Genentech/Roche; Guardant Health; Guerbet; Halozyme; Helsinn; Immunogen; IntegraGen; Lexicon; Lilly; Novartis; Oncosil; Opsona Therapeutics; Pfizer; Purdue Pharma; Rafael Pharmaceuticals; Taiho Pharmaceutical; TRM Oncology
Research Funding - Acerta Pharma; advanced accelerator applications (Inst); Bristol-Myers Squibb; Celgene; Infinity Pharmaceuticals (Inst); MedImmune; Merck Sharp & Dohme (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Xencor; Xencor
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; DAVAOncology; Genentech/Roche; Gilead Sciences; Guardant Health; guerbet; Helsinn; Lilly/ImClone; Sanofi; Spectrum Pharmaceuticals; TRM Oncology